{"protocolSection": {"identificationModule": {"nctId": "NCT00482729", "orgStudyIdInfo": {"id": "0431A-079"}, "secondaryIdInfos": [{"id": "MK0431A-079"}, {"id": "2007_548"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)", "officialTitle": "A Randomized, Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of MK0431A for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)"}, "statusModule": {"statusVerifiedDate": "2017-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-06-19", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2008-11-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-04-27", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-05-31", "studyFirstSubmitQcDate": "2007-06-01", "studyFirstPostDateStruct": {"date": "2007-06-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-12-09", "resultsFirstSubmitQcDate": "2010-03-02", "resultsFirstPostDateStruct": {"date": "2010-03-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-05-11", "lastUpdatePostDateStruct": {"date": "2017-06-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to investigate the efficacy and safety of an investigational treatment for type 2 diabetes mellitus."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1246, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Arm 1: drug", "interventionNames": ["Drug: sitagliptin phosphate (+) metformin hydrochloride"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Arm 2: active comparator", "interventionNames": ["Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "sitagliptin phosphate (+) metformin hydrochloride", "description": "sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.", "armGroupLabels": ["1"], "otherNames": ["MK0431A", "Janumet\u2122"]}, {"type": "DRUG", "name": "metformin", "description": "metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1c (A1C) at Week 18", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.", "timeFrame": "Baseline and Week 18"}], "secondaryOutcomes": [{"measure": "Number of Patients With A1C < 7.0% at Week 18", "timeFrame": "Week 18"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18", "description": "FPG is measured as mg/dL. Thus, this change from baseline reflects the Week 18 FPG mg/dL minus the Week 0 FPG mg/dL.", "timeFrame": "Baseline and Week 18"}], "otherOutcomes": [{"measure": "Change From Baseline in A1C at Week 44", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 44 A1C percent minus the Week 0 A1C percent.", "timeFrame": "Baseline and Week 44"}, {"measure": "Number of Patients With A1C < 7.0% at Week 44", "timeFrame": "Week 44"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Patient is greater than or equal to 18 and less than or equal to 78 years of age on the day of signing the consent\n* Patient has Hb1Ac greater than or equal to 7.5% and is appropriate for oral therapy\n* Patient has not been on any antihyperglycemic agent (AHA) in the last 4 months\n* Patient is a male, or a female who is unlikely to conceive\n\nExclusion Criteria:\n\n* Patient has type 1 diabetes mellitus or history of ketoacidosis", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "21410627", "type": "RESULT", "citation": "Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnson-Levonas AO, Kaufman KD, Goldstein BJ. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011 Jul;13(7):644-52. doi: 10.1111/j.1463-1326.2011.01390.x."}, {"pmid": "21535346", "type": "RESULT", "citation": "Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, Mehta A, Kaufman KD, Goldstein BJ. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab. 2011 Sep;13(9):841-9. doi: 10.1111/j.1463-1326.2011.01416.x."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients 18-78 years of age with type 2 diabetes mellitus (T2DM) with inadequate glycemic control (hemoglobin A1c \\[A1C\\] \\>7.5% at screening visit) who were appropriate for treatment with oral antihyperglycemic therapy and had not been on an anti-hyperglycemic agent (AHA) in the last 4 months were eligible to participate.", "recruitmentDetails": "First Patient In: 26-Jun-2007; Last Patient Last Visit for end of study: 28-Apr-2009; Two-hundred four medical clinics in the United States (US) and 5 in Puerto Rico.", "groups": [{"id": "FG000", "title": "Sita/Met FDC", "description": "The Sitagliptin/Metformin Fixed Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met initiated at a dose of 50/500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 50/1000 mg b.i.d.; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}, {"id": "FG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with oral tablets of metformin initiated at a dose of 500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 1000 mg b.i.d. ; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Site 079011301 was identified as non-compliant and 1 patient was excluded from all analysis", "numSubjects": "626"}, {"groupId": "FG001", "comment": "Site 079011301 was identified as non-compliant and 3 patients were excluded from all analysis", "numSubjects": "624"}]}, {"type": "Completed Phase A", "achievements": [{"groupId": "FG000", "numSubjects": "484"}, {"groupId": "FG001", "numSubjects": "482"}]}, {"type": "Completed Phase B", "achievements": [{"groupId": "FG000", "numSubjects": "409"}, {"groupId": "FG001", "numSubjects": "406"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "409"}, {"groupId": "FG001", "numSubjects": "406"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "217"}, {"groupId": "FG001", "numSubjects": "218"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "33"}]}, {"type": "Creatinine/Creatinine Clearance Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Hyperglycemia Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "86"}, {"groupId": "FG001", "numSubjects": "66"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "67"}, {"groupId": "FG001", "numSubjects": "69"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sita/Met FDC", "description": "The Sitagliptin/Metformin Fixed Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met initiated at a dose of 50/500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 50/1000 mg b.i.d.; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}, {"id": "BG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with oral tablets of metformin initiated at a dose of 500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 1000 mg b.i.d. ; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "625"}, {"groupId": "BG001", "value": "621"}, {"groupId": "BG002", "value": "1246"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49.4", "spread": "10.5"}, {"groupId": "BG001", "value": "50.0", "spread": "10.5"}, {"groupId": "BG002", "value": "49.7", "spread": "10.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "272"}, {"groupId": "BG001", "value": "266"}, {"groupId": "BG002", "value": "538"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "353"}, {"groupId": "BG001", "value": "355"}, {"groupId": "BG002", "value": "708"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "41"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "82"}, {"groupId": "BG001", "value": "88"}, {"groupId": "BG002", "value": "170"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "508"}, {"groupId": "BG001", "value": "489"}, {"groupId": "BG002", "value": "997"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "38"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.91", "spread": "1.83"}, {"groupId": "BG001", "value": "9.83", "spread": "1.77"}, {"groupId": "BG002", "value": "9.87", "spread": "1.80"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1c (A1C) at Week 18", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.", "populationDescription": "The Full Analysis Set (FAS) included all patients who received at least 1 dose of double-blind study therapy, had a baseline value and \u2265 1 post-baseline value for this outcome. Data after initiation of additional AHA were treated as missing. For FAS with no data at Week 18, the last post-baseline observed measurement was carried forward to Week 18.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 18", "groups": [{"id": "OG000", "title": "Sita/Met FDC", "description": "The Sitagliptin/Metformin Fixed Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met initiated at a dose of 50/500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 50/1000 mg b.i.d.; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with oral tablets of metformin initiated at a dose of 500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 1000 mg b.i.d. ; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "559"}, {"groupId": "OG001", "value": "564"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.37", "lowerLimit": "-2.49", "upperLimit": "-2.24"}, {"groupId": "OG001", "value": "-1.76", "lowerLimit": "-1.88", "upperLimit": "-1.64"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, baseline A1C", "paramType": "Mean Difference (Net)", "paramValue": "-0.60", "ciPctValue": "95", "ciLowerLimit": "-0.78", "ciUpperLimit": "-0.43"}]}, {"type": "SECONDARY", "title": "Number of Patients With A1C < 7.0% at Week 18", "populationDescription": "The Full Analysis Set (FAS) included all patients who received at least 1 dose of double-blind study therapy, had a baseline value and \u22651 post-baseline value for this outcome. Data after initiation of additional AHA were treated as missing. For FAS with no data at Week 18, the last post-baseline observed measurement was carried forward to Week 18.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 18", "groups": [{"id": "OG000", "title": "Sita/Met FDC", "description": "The Sitagliptin/Metformin Fixed Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met initiated at a dose of 50/500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 50/1000 mg b.i.d.; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with oral tablets of metformin initiated at a dose of 500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 1000 mg b.i.d. ; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "559"}, {"groupId": "OG001", "value": "564"}]}], "classes": [{"title": "Patients with A1C <7.0% at Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "193"}]}]}, {"title": "Patients with A1C \u22657.0% at Week 18", "categories": [{"measurements": [{"groupId": "OG000", "value": "284"}, {"groupId": "OG001", "value": "371"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Based on a test of the odds ratio = 1, comparing the odds of having A1C \\<7.0% at Week 18 in the Sita/Met FDC group vs. the Metformin group.", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, baseline A1C", "paramType": "Odds Ratio (OR)", "paramValue": "2.07", "ciPctValue": "95", "ciLowerLimit": "1.60", "ciUpperLimit": "2.69", "estimateComment": "This parameter estimate and 95% confidence interval correspond to the odds of having A1C \\<7.0% at Week 18 in the Sita/Met FDC group vs. the Metformin group."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18", "description": "FPG is measured as mg/dL. Thus, this change from baseline reflects the Week 18 FPG mg/dL minus the Week 0 FPG mg/dL.", "populationDescription": "The Full Analysis Set (FAS) included all patients who received at least 1dose of double-blind study therapy, had a baseline value and \u22651 post-baseline value for this outcome. Data after initiation of additional AHA were treated as missing. For FAS with no data at Week 18, the last post-baseline observed measurement was carried forward to Week 18.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 18", "groups": [{"id": "OG000", "title": "Sita/Met FDC", "description": "The Sitagliptin/Metformin Fixed Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met initiated at a dose of 50/500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 50/1000 mg b.i.d.; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with oral tablets of metformin initiated at a dose of 500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 1000 mg b.i.d. ; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "560"}, {"groupId": "OG001", "value": "566"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-69.4", "lowerLimit": "-74.1", "upperLimit": "-64.6"}, {"groupId": "OG001", "value": "-53.7", "lowerLimit": "-58.4", "upperLimit": "-48.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, baseline A1C", "paramType": "Mean Difference (Net)", "paramValue": "-15.7", "ciPctValue": "95", "ciLowerLimit": "-22.4", "ciUpperLimit": "-9.0"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in A1C at Week 44", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 44 A1C percent minus the Week 0 A1C percent.", "populationDescription": "The Full Analysis Set (FAS) included all patients who received at least 1 dose of double-blind study therapy, had a baseline value and \u22651 post-baseline value for this outcome. Data after initiation of additional AHA were included. For FAS with no data at Week 44, the last post-baseline observed measurement was carried forward to Week 44.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 44", "groups": [{"id": "OG000", "title": "Sita/Met FDC", "description": "The Sitagliptin/Metformin Fixed Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met initiated at a dose of 50/500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 50/1000 mg b.i.d.; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with oral tablets of metformin initiated at a dose of 500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 1000 mg b.i.d. ; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "560"}, {"groupId": "OG001", "value": "569"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.25", "lowerLimit": "-2.38", "upperLimit": "-2.12"}, {"groupId": "OG001", "value": "-1.77", "lowerLimit": "-1.89", "upperLimit": "-1.64"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-0.48", "ciPctValue": "95", "ciLowerLimit": "-0.67", "ciUpperLimit": "-0.30", "estimateComment": "This is a difference in least squares means, based on an ANCOVA model with terms for treatment and baseline (i.e., Week 0) A1C."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Patients With A1C < 7.0% at Week 44", "populationDescription": "The Full Analysis Set (FAS) included all patients who received at least 1dose of double-blind study therapy, had a baseline value and \u22651 post-baseline value for this outcome. Data after initiation of additional AHA were included. For FAS with no data at Week 44, the last post-baseline observed measurement was carried forward to Week 44.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 44", "groups": [{"id": "OG000", "title": "Sita/Met FDC", "description": "The Sitagliptin/Metformin Fixed Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met initiated at a dose of 50/500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 50/1000 mg b.i.d.; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}, {"id": "OG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with oral tablets of metformin initiated at a dose of 500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 1000 mg b.i.d. ; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "560"}, {"groupId": "OG001", "value": "569"}]}], "classes": [{"title": "Patients with A1C <7.0% at Week 44", "categories": [{"measurements": [{"groupId": "OG000", "value": "258"}, {"groupId": "OG001", "value": "173"}]}]}, {"title": "Patients with A1C \u22657.0% at Week 44", "categories": [{"measurements": [{"groupId": "OG000", "value": "302"}, {"groupId": "OG001", "value": "396"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Odds Ratio (OR)", "paramValue": "2.11", "ciPctValue": "95", "ciLowerLimit": "1.63", "ciUpperLimit": "2.73", "estimateComment": "This parameter estimate and 95% confidence interval correspond to the odds of having A1C \\<7.0% at Week 44 in the Sita/Met FDC group vs. the Metformin group, based on a logistic regression model with terms for treatment and baseline (i.e., Week 0) A1C"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Week 0 through Week 44", "description": "1 patient in the Sita/Met FDC group and 3 patients in the Metformin group from Site 079011301, which was identified as non-compliant with some of the requirements of Good Clinical Practice. For this reason, data from all four randomized patients at this site were deemed unreliable and were excluded from the primary efficacy and safety analysis.", "eventGroups": [{"id": "EG000", "title": "Sita/Met FDC", "description": "The Sitagliptin/Metformin Fixed Dose Combination (Sita/Met FDC) group includes data from patients randomized to receive treatment with oral tablets of Sita/Met initiated at a dose of 50/500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 50/1000 mg b.i.d.; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated.", "seriousNumAffected": 28, "seriousNumAtRisk": 625, "otherNumAffected": 173, "otherNumAtRisk": 625}, {"id": "EG001", "title": "Metformin", "description": "The Metformin group includes data from patients randomized to receive treatment with oral tablets of metformin initiated at a dose of 500 mg twice a day (b.i.d.) The dose was to have been up-titrated over 4 weeks to 1000 mg b.i.d. ; however, patients could stay in the study on a minimum dose of Sita/Met 50/500 mg b.i.d. if a higher dose was not tolerated.", "seriousNumAffected": 38, "seriousNumAtRisk": 621, "otherNumAffected": 185, "otherNumAtRisk": 621}], "seriousEvents": [{"term": "Any Cardiac Disorders", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 621}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 621}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Any Gastrointestinal Disorders", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 621}]}, {"term": "Food poisoning", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Pancreatitis chronic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Any General Disorders and Administration site Conditions", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 621}]}, {"term": "Adverse drug reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Electrocution", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Any Hepatobiliary disorders", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 621}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Any Infections and Infestations", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 621}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Enterocolitis infectious", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Hepatitis C", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Pneumonia streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Any Injury, Poisoning and Procedural Complications", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 621}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Pneumothorax traumatic", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Skull fractured base", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Any Metabolism and Nutrition Disorders", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 621}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Diabetic foot", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Any Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 621}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Endometrial cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Laryngeal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Lung adenocarcinoma metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Metastatic renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Ovarian adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Prostate cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Any Nervous System Disorders", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 621}]}, {"term": "Carotid artery disease", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 621}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 621}]}, {"term": "Any Pregnancy, puerperium and perinatal conditions", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Any Psychiatric Disorders", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 621}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Panic attack", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Schizophrenia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 621}]}, {"term": "Any Renal and Urinary Disorders", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 621}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Neurogenic bladder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Postrenal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Any Respiratory, Thoracic and Mediastinal Disorders", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Respiratory distress", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Any Vascular Disorders", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 621}]}, {"term": "Aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Aortic aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Aortic stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 621}]}, {"term": "Thrombophlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 621}]}], "otherEvents": [{"term": "Any Gastrointestinal Disorders", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 107, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 136, "numAtRisk": 621}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 86, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 112, "numAtRisk": 621}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 37, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 44, "numAtRisk": 621}]}, {"term": "Any Infections and infestations", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 62, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 57, "numAtRisk": 621}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 26, "numAtRisk": 621}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 621}]}, {"term": "Any Nervous system disorders", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 621}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 625}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 621}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Site 079011301 was non-compliant with Good Clinical Practice (GCP). Data from the 4 patients at this site are included in the Participant Flow summary, but are excluded from all other summaries and analyses."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Puerto Rico", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Dextromethorphan", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}